Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
- PMID: 28919117
- PMCID: PMC5605509
- DOI: 10.1016/S0140-6736(17)32154-2
Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
Erratum in
-
Department of Error.Lancet. 2017 Oct 28;390(10106):e38. doi: 10.1016/S0140-6736(17)32647-8. Epub 2017 Oct 13. Lancet. 2017. PMID: 29032994 Free PMC article. No abstract available.
Abstract
Background: As mortality rates decline, life expectancy increases, and populations age, non-fatal outcomes of diseases and injuries are becoming a larger component of the global burden of disease. The Global Burden of Diseases, Injuries, and Risk Factors Study 2016 (GBD 2016) provides a comprehensive assessment of prevalence, incidence, and years lived with disability (YLDs) for 328 causes in 195 countries and territories from 1990 to 2016.
Methods: We estimated prevalence and incidence for 328 diseases and injuries and 2982 sequelae, their non-fatal consequences. We used DisMod-MR 2.1, a Bayesian meta-regression tool, as the main method of estimation, ensuring consistency between incidence, prevalence, remission, and cause of death rates for each condition. For some causes, we used alternative modelling strategies if incidence or prevalence needed to be derived from other data. YLDs were estimated as the product of prevalence and a disability weight for all mutually exclusive sequelae, corrected for comorbidity and aggregated to cause level. We updated the Socio-demographic Index (SDI), a summary indicator of income per capita, years of schooling, and total fertility rate. GBD 2016 complies with the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER).
Findings: Globally, low back pain, migraine, age-related and other hearing loss, iron-deficiency anaemia, and major depressive disorder were the five leading causes of YLDs in 2016, contributing 57·6 million (95% uncertainty interval [UI] 40·8-75·9 million [7·2%, 6·0-8·3]), 45·1 million (29·0-62·8 million [5·6%, 4·0-7·2]), 36·3 million (25·3-50·9 million [4·5%, 3·8-5·3]), 34·7 million (23·0-49·6 million [4·3%, 3·5-5·2]), and 34·1 million (23·5-46·0 million [4·2%, 3·2-5·3]) of total YLDs, respectively. Age-standardised rates of YLDs for all causes combined decreased between 1990 and 2016 by 2·7% (95% UI 2·3-3·1). Despite mostly stagnant age-standardised rates, the absolute number of YLDs from non-communicable diseases has been growing rapidly across all SDI quintiles, partly because of population growth, but also the ageing of populations. The largest absolute increases in total numbers of YLDs globally were between the ages of 40 and 69 years. Age-standardised YLD rates for all conditions combined were 10·4% (95% UI 9·0-11·8) higher in women than in men. Iron-deficiency anaemia, migraine, Alzheimer's disease and other dementias, major depressive disorder, anxiety, and all musculoskeletal disorders apart from gout were the main conditions contributing to higher YLD rates in women. Men had higher age-standardised rates of substance use disorders, diabetes, cardiovascular diseases, cancers, and all injuries apart from sexual violence. Globally, we noted much less geographical variation in disability than has been documented for premature mortality. In 2016, there was a less than two times difference in age-standardised YLD rates for all causes between the location with the lowest rate (China, 9201 YLDs per 100 000, 95% UI 6862-11943) and highest rate (Yemen, 14 774 YLDs per 100 000, 11 018-19 228).
Interpretation: The decrease in death rates since 1990 for most causes has not been matched by a similar decline in age-standardised YLD rates. For many large causes, YLD rates have either been stagnant or have increased for some causes, such as diabetes. As populations are ageing, and the prevalence of disabling disease generally increases steeply with age, health systems will face increasing demand for services that are generally costlier than the interventions that have led to declines in mortality in childhood or for the major causes of mortality in adults. Up-to-date information about the trends of disease and how this varies between countries is essential to plan for an adequate health-system response.
Funding: Bill & Melinda Gates Foundation, and the National Institute on Aging and the National Institute of Mental Health of the National Institutes of Health.
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Figures














Comment in
-
Underestimation of the global burden of schistosomiasis.Lancet. 2018 Jan 27;391(10118):307-308. doi: 10.1016/S0140-6736(18)30098-9. Epub 2018 Jan 31. Lancet. 2018. PMID: 29413041 No abstract available.
Similar articles
-
Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.Lancet. 2018 Nov 10;392(10159):1789-1858. doi: 10.1016/S0140-6736(18)32279-7. Epub 2018 Nov 8. Lancet. 2018. PMID: 30496104 Free PMC article.
-
Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.Lancet. 2015 Aug 22;386(9995):743-800. doi: 10.1016/S0140-6736(15)60692-4. Epub 2015 Jun 7. Lancet. 2015. PMID: 26063472 Free PMC article. Review.
-
Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016.Lancet. 2017 Sep 16;390(10100):1151-1210. doi: 10.1016/S0140-6736(17)32152-9. Lancet. 2017. PMID: 28919116 Free PMC article.
-
Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.Lancet. 2016 Oct 8;388(10053):1545-1602. doi: 10.1016/S0140-6736(16)31678-6. Lancet. 2016. PMID: 27733282 Free PMC article.
-
Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010.Lancet. 2013 Nov 9;382(9904):1575-86. doi: 10.1016/S0140-6736(13)61611-6. Epub 2013 Aug 29. Lancet. 2013. PMID: 23993280 Review.
Cited by
-
A systematic review of movement and muscular activity biomarkers to discriminate non-specific chronic low back pain patients from an asymptomatic population.Sci Rep. 2021 Mar 12;11(1):5850. doi: 10.1038/s41598-021-84034-x. Sci Rep. 2021. PMID: 33712658 Free PMC article.
-
Acceptability of a nationwide scabies mass drug administration (MDA) program in Fiji: a qualitative interview-based study.Lancet Reg Health West Pac. 2024 Sep 4;51:101194. doi: 10.1016/j.lanwpc.2024.101194. eCollection 2024 Oct. Lancet Reg Health West Pac. 2024. PMID: 39295851 Free PMC article.
-
Progress and trends of research on mineral elements for depression.Heliyon. 2024 Jul 31;10(15):e35469. doi: 10.1016/j.heliyon.2024.e35469. eCollection 2024 Aug 15. Heliyon. 2024. PMID: 39170573 Free PMC article.
-
Migraine Disability, Quality of Life, and Its Predictors.Ann Neurosci. 2020 Jan;27(1):18-23. doi: 10.1177/0972753120929563. Epub 2020 Jul 3. Ann Neurosci. 2020. PMID: 32982095 Free PMC article.
-
Exploring Emotional Distress, Psychological Traits and Attitudes in Patients with Chronic Migraine Undergoing OnabotulinumtoxinA Prophylaxis versus Withdrawal Treatment.Toxins (Basel). 2020 Sep 8;12(9):577. doi: 10.3390/toxins12090577. Toxins (Basel). 2020. PMID: 32911799 Free PMC article.
References
-
- Nino F. United Nations Sustainable Development Goals. UNDP. http://www.undp.org/content/undp/en/home/sustainable-development-goals.html (accessed March 10, 2017).
MeSH terms
Grants and funding
- MR/K00669X/1/MRC_/Medical Research Council/United Kingdom
- R01 MH110163/MH/NIMH NIH HHS/United States
- U01 AG009740/AG/NIA NIH HHS/United States
- P30 AG047845/AG/NIA NIH HHS/United States
- SPHSU15/CSO_/Chief Scientist Office/United Kingdom
- MC_UU_12011/2/MRC_/Medical Research Council/United Kingdom
- MC_UP_A620_1014/MRC_/Medical Research Council/United Kingdom
- R01 HD084233/HD/NICHD NIH HHS/United States
- R01 HD087993/HD/NICHD NIH HHS/United States
- MC_U147585827/MRC_/Medical Research Council/United Kingdom
- WT_/Wellcome Trust/United Kingdom
- MC_UU_12017/15/MRC_/Medical Research Council/United Kingdom
- MR/K013351/1/MRC_/Medical Research Council/United Kingdom
- MC_UP_A620_1015/MRC_/Medical Research Council/United Kingdom
- CDF-2011-04-048/DH_/Department of Health/United Kingdom
- 201900/Z/16/Z/WT_/Wellcome Trust/United Kingdom
- P01 HD031921/HD/NICHD NIH HHS/United States
- SCAF/15/02/CSO_/Chief Scientist Office/United Kingdom
- U01 AI096299/AI/NIAID NIH HHS/United States
- MC_UU_12017/13/MRC_/Medical Research Council/United Kingdom
- D43 TW009775/TW/FIC NIH HHS/United States
- G0400491/MRC_/Medical Research Council/United Kingdom
- MC_U147585819/MRC_/Medical Research Council/United Kingdom
- MC_UU_12011/1/MRC_/Medical Research Council/United Kingdom
- 201900/WT_/Wellcome Trust/United Kingdom
- SPHSU13/CSO_/Chief Scientist Office/United Kingdom
- HHSN271201300071C/AG/NIA NIH HHS/United States
- N01HC25195/HL/NHLBI NIH HHS/United States
- R01 AI124389/AI/NIAID NIH HHS/United States
- UL1 TR001881/TR/NCATS NIH HHS/United States
- P01 AG041710/AG/NIA NIH HHS/United States
- MC_U147585824/MRC_/Medical Research Council/United Kingdom
- R01 AI112339/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials